NanoViricides, Inc. (NYSE American: NNVC) announced that its President, Dr. Anil R. Diwan, was interviewed on the Mission Matters Podcast, where he discussed the company's innovative approach to antiviral therapy and the progress of its lead drug candidate, NV-387. The interview underscored the potential of nanoviricides to overcome limitations of traditional antiviral treatments, offering broad-spectrum efficacy independent of patient immune status.
During the podcast, Dr. Diwan explained that nanoviricides are designed to mimic host cell receptors, binding to viruses and preventing their escape, thereby neutralizing them regardless of the patient's immune response. This mechanism allows the platform to work across diverse patient populations, from infants to the elderly. He highlighted that NV-387 has demonstrated effectiveness against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles. Notably, the drug candidate completed a Phase I clinical trial with no reported adverse events, indicating a favorable safety profile.
Dr. Diwan also revealed that a Phase II clinical trial for NV-387 targeting MPox is ready to commence in the Democratic Republic of Congo, following regulatory clearance. This positions NV-387 as a potential empirical therapy for acute respiratory and other viral infections. The market opportunity for such a broad-spectrum antiviral is estimated to exceed $17 billion by 2030, according to the company. For more details, the full press release is available at https://ibn.fm/EqHoV.
NanoViricides is a clinical-stage company specializing in nanomaterials for antiviral therapy. Its lead candidate, NV-387, is being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPox and Smallpox. The company also has advanced drug candidates, including NV-HHV-1 for Shingles. The company's platform technology is based on intellectual property licensed from TheraCour Pharma, Inc. Investors can stay updated on NNVC news at https://ibn.fm/NNVC.
The interview highlighted the significance of NanoViricides' approach in addressing the urgent need for broad-spectrum antivirals, especially in the wake of the COVID-19 pandemic. Dr. Diwan emphasized that the nanoviricide platform could provide a rapid response to emerging viral threats, as it can be adapted to target new viruses by modifying the ligand on the nanomicelle. This adaptability could be crucial for pandemic preparedness. The company's focus on advancing NV-387 into Phase II trials marks a critical step toward validating this technology in humans.
